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Characteristics of the patients
n
Number 8
Follow-up period (days), median (range) 290 (141–400)
Age range (years) 18–51
Male/female 4/4
Disease
AML
CR1 1
NR 4
ALL
CR1 2
NR 1
Conditioning
TBI +CA(G) + Flu 3
TBI +CA+CY 3
TBI +CA(G) +CY 2
GVHD prophylaxis
Cyclosporine +MTX 7
Cyclosporine 1
GVHD
Grade I 4
Grade II 3
Grade III 1
Steroid use 8
Relapse 1
AML, acute myelogenous leukemia; CR1, ﬁrst complete remission; NCR, non-
complete remission; ALL, acute lymphoblastic leukemia; TBI, total body irradiation;
CA, cytosine arabinoside; CA(G), granulocyte colony-stimulating factor-combined
cytosine arabinoside; Flu, ﬂudarabine; CY, cyclophosphamide; GVHD, graft-versus-
host-disease; MTX, methotrexate.Low-dose acyclovir against reactivation of varicella zoster virus
after unrelated cord blood transplantation
Varicella zoster virus (VZV) infection remains a major cause of
morbidity and mortality after hematopoietic stem cell transplan-
tation (HSCT). Infection with VZV develops as a reactivation of
latent virus mainly between 3 and 12 month after transplantation,
with a cumulative incidence of >30%.1 Localized dermatomal rash
is the most frequent clinical presentation, but it can lead to serious
complications, including dissemination (cutaneous or visceral),
hepatic disease, post-herpetic neuralgia, bacterial superinfection,
and death after HSCT. The effect of long-term prophylaxis with
low-dose acyclovir (ACV) against VZV reactivation has therefore
been discussed.2–4
The incidence of umbilical cord blood transplantation (CBT)
from unrelated donors has recently increased among adult
patients with hematological diseases for whom suitable related
or unrelated donors are unavailable.5–7 However, the impact of
prophylactic ACV onVZV reactivation in the setting of post-CBT has
not been discussed. The characteristics of immune reconstitution
differ after CBT compared with HSCT using other stem cell sources,
and this might lead to a difference in the rates of VZV
reactivation.8,9
We examined the effects of long-term ACV prophylaxis
(400 mg/day) in patients after CBT. Although our patient cohort
is small, we believe that the impact of prophylactic low-dose ACV
against reactivation of VZV after CBT is signiﬁcant and positive.
We analyzed eight VZV-seropositive patients who underwent a
myeloablative regimen, involving total body irradiation followed
by CBT from unrelated donors, at Shizuoka Cancer Center between
January and August 2008. Patients who remained free of VZV
reactivation after CBT were censored at the time of their last
follow-up or death. Engraftment was successful in all patients.
Table 1 shows their characteristics. The median numbers of total
nucleated cells and CD34-positive cells in the CB units were 2.33
107/kg and 1.14  105/kg of recipient body weight, respectively.
Graft-versus-host-disease (GVHD) prophylaxis comprised cyclos-
porine (CSP; 3 mg/kg/day) with a short course of methotrexate for
all but one patient who received only CSP. Intravenous immu-
noglobulin was administered from day 1 to day 100 when serum
immunoglobulin levels fell below 5 g/l (500 mg/dl). All of the
patients received oral ACV (1000 mg/day) from day 10 to day 35,
followed by 400 mg/day ACV (200 mg twice daily). When
creatinine clearance was <50 ml/min, the ACV dose was reduced
to 200 mg/day. Based on the results of the CMV antigenemia
assays, pre-emptive therapy was administered for 14 days with
daily doses of either intravenous ganciclovir (5 mg/kg) or foscarnet
(90 mg/kg).
The median follow-up period was 290 days. All patients were
given steroid during their clinical course. One patient developed
dermatomal VZV infection on day 299 while the patient was1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.06.007unable to tolerate oral ACV. The patient responded well to
therapeutic intravenous ACV. Cytomegalovirus antigenemia devel-
oped in seven patients, but herpes simplex virus was not
reactivated in any patient.
Tomonari et al. described VZV reactivation in 40 adult patients
after CBT from unrelated donors in a single institution.8 Twenty-
ﬁve of their patients developed VZV reactivation at a median of 5
months after CBT, and the cumulative incidence at 30 months was
80%. However, that study did not routinely administer long-term
ACV prophylaxis against VZV reactivation.
We have routinely administered ACV (400 mg/day) to patients
undergoing CBT until the end of immunosuppressive therapy or for
at least one year after HSCT with promising results. Considering
that herpes zoster reactivated in only one of our patients while he
was unable to tolerate oral ACV, the optimal duration of ACV
prophylaxis leaves much to be discussed.
In conclusion, our ﬁndings indicate that 400 mg/day of ACV
administered after post-transplantation day 35 is a safe and
effective strategy to prevent clinical VZV reactivation in CBTses. Published by Elsevier Ltd. All rights reserved.
Letter to the Editor / International Journal of Infectious Diseases 14 (2010) e451–e452e452recipients. Althoughwe have not yet evaluated the effectiveness of
low-dose ACV against VZV reactivation for >1 year, such
prophylaxis shows promise in the CBT setting as well as in HSCT
with other stem cell sources.
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